Company Overview and News

1
National Vision Holdings, Inc. Appoints Thomas V. Taylor, Jr. to Board of Directors

2018-09-10 globenewswire
DULUTH, Ga., Sept. 10, 2018 (GLOBE NEWSWIRE) -- National Vision Holdings, Inc. (NASDAQ: EYE), one of the nation’s largest optical retailers providing quality, affordable eye care and eyewear, today announced the appointment of Thomas V. Taylor, Jr., Chief Executive Officer of Floor & Decor Holdings, Inc. (Floor & Decor), to its Board of Directors, effective today. Mr. Taylor will serve on the Board’s Audit and Compensation Committees.
HD EYE

1
National Vision Holdings 2018 Q2 - Results - Earnings Call Slides

2018-08-14 seekingalpha
The following slide deck was published by National Vision Holdings in conjunction with their 2018 Q2 earnings call.
EYE

4
Can Molecular Diagnostics Drive Myriad's (MYGN) Q4 Earnings?

2018-08-13 zacks
Myriad Genetics, Inc. (MYGN - Free Report) is scheduled to report fourth-quarter fiscal 2018 results on Aug 14, after the closing bell.
FOX EYE MYGN LMHA AAP LMHB FOXA LM

93
EYE / National Vision Holdings, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-08-10 fintel.io
This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
TWMJF EYE BLK NYMX WEED HSIC CGC

1
EYE / National Vision Holdings, Inc. / FMR LLC / Fidelity - null (Passive Investment)

2018-08-10 sec.gov
SCHEDULE 13G Amendment No. 0 NATIONAL VISION HLDGS INC COMMON STOCK Cusip #63845R107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #63845R107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,061,509 Item 6: 0 Item 7: 9,657,511 Item 8: 0 Item 9: 9,657,511 Item 11: 12.
EYE

1
EYE / National Vision Holdings, Inc. / FMR LLC / Fidelity - null (Passive Investment)

2018-08-10 sec.gov
SCHEDULE 13G Amendment No. 0 NATIONAL VISION HLDGS INC COMMON STOCK Cusip #63845R107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #63845R107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,061,509 Item 6: 0 Item 7: 9,657,511 Item 8: 0 Item 9: 9,657,511 Item 11: 12.
EYE

8
What's in Store for Penumbra (PEN) This Earnings Season?

2018-08-06 zacks
Penumbra, Inc. (PEN - Free Report) is expected to report second-quarter 2018 results on Aug 7, after market close.
ARDX MKGAF EYE MKGAY NTRA PEN BGSF

8
Can Dental Growth Drive Henry Schein's (HSIC) Q2 Earnings?

2018-08-02 zacks
Henry Schein, Inc. (HSIC - Free Report) is expected to report second-quarter 2018 results on Aug 6. Last reported quarter, the company’s earnings exceeded the Zacks Consensus Estimate by 3 cents. Overall, the metric surpassed estimates in two of the last four quarters, the average positive surprise being 0.27%.
ARDX EYE XRAY NTRA ENR HSIC

1
National Vision Celebrates the Importance of Eye Exams and Helping Kids Prepare for Back-to-School

2018-08-01 globenewswire
DULUTH, Ga., Aug. 01, 2018 (GLOBE NEWSWIRE) -- National Vision Holdings, Inc. (NASDAQ:EYE), one of the nation’s largest optical retailers providing quality, affordable eye care and eyewear, is proud to join in the optical industry’s celebration of August as National Eye Exam Month, Children’s Eye Health and Safety Awareness Month, and Children’s Vision and Learning Month.
EYE

1
National Vision Holdings, Inc. Announces Second Quarter 2018 Earnings Release and Conference Call

2018-07-30 globenewswire
DULUTH, Ga., July 30, 2018 (GLOBE NEWSWIRE) -- National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) will report its second quarter 2018 financial results before the market opens on Tuesday, August 14, 2018.
EYE

1

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to EYE / National Vision Holdings, Inc. on message board site Silicon Investor.

FireEye, Inc. (FEYE) - cybersecurity FireEye, Inc. (FEYE) - cybersecurity FireEye, Inc. (FEYE) - cybersecurity EYES Second Sight-Eyeglasses for the Blind help them see EYES Second Sight-Eyeglasses for the Blind help them see EYES Second Sight-Eyeglasses for the Blind help them see
Blue Eyes Crying in the Rain Blue Eyes Crying in the Rain Blue Eyes Crying in the Rain Mobileye Mobileye Mobileye
HAWKEYE Gold Grants 985,000 Incentive Stock Options HAWKEYE Gold Grants 985,000 Incentive Stock Options HAWKEYE Gold Grants 985,000 Incentive Stock Options HAWKEYE Gold Grants 985,000 Incentive Stock Options HAWKEYE Gold Grants 985,000 Incentive Stock Options HAWKEYE Gold Grants 985,000 Incentive Stock Options
HAWKEYE GOLD PURCHASE TOP PROPERTY - YUKON HAWKEYE GOLD PURCHASE TOP PROPERTY - YUKON HAWKEYE GOLD PURCHASE TOP PROPERTY - YUKON HAWKEYE GOLD. TSX SYMBOL - HGO HAWKEYE GOLD. TSX SYMBOL - HGO HAWKEYE GOLD. TSX SYMBOL - HGO
Intellicorp - Keep A Watchful Eye On It Intellicorp - Keep A Watchful Eye On It Intellicorp - Keep A Watchful Eye On It Keep Your Eye On The Ball - Watch List Keep Your Eye On The Ball - Watch List Keep Your Eye On The Ball - Watch List
CUSIP: 63845R107